NCT06541548Recruiting
Comparison of Bone Microarchitecture Analysed by HRpQCT and pQCT in Pathologies With Bone Loss and/or Muscle Loss
Comparison of Bone Microarchitecture Analysed by High Resolution Peripheral Microscanner (HR-pQCT) and Peripheral Microscanner (pQCT) in Pathologies With Bone Loss and/or Muscle Loss
Source: ClinicalTrials.gov · Last updated 3 Mar 2026
Brief summary (registry, in English)
The study aims to utilize medical devices, such as the Xtreme CT and XCT 3000, to assess bone and muscle microarchitecture for various pathologies. The devices provide crucial data on bone and muscle density, aiding in understanding fracture risks associated with conditions like rheumatoid arthritis and neurological disorders. Current methods like DXA scanning have limitations in predicting fracture risks accurately due to their inability to assess cortical and trabecular microstructure. The study emphasizes the importance of evaluating cortical porosity and trabecular volume loss, especially in conditions like post-menopausal osteoporosis and sarcopenia. Additionally, it explores the impact of neurological disorders, renal insufficiency, and endocrinopathies on bone health. Furthermore, the study aims to establish a control group to differentiate pathological changes from age-related variations. Expected outcomes include a comprehensive understanding of bone microarchitecture alterations across various pathologies and the potential to improve fracture risk estimation beyond conventional methods like DEXA scanning. Ultimately, the study anticipates facilitating better management strategies to reduce fracture risks associated with these conditions.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 1000 (estimated)
- First submitted
- 25 Jul 2024
- Start date
- 2 Feb 2026
- Primary completion date
- 31 May 2035
- Lead sponsor
- Centre Hospitalier Universitaire de Saint Etienne
- Diseases
- Osteoporosis
- NCT number
- NCT06541548
What you commit to
- Study type: Interventional
- Planned participants: 1000
- From 2 Feb 2026 to the primary completion date, 31 May 2035
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Medications inducing bone loss:
- corticosteroids (dose ≥ 5 mg/d for 6 months)
- anti-epileptic drugs: carbamazepine, phenobarbital, phenytoin, primidone, valproic acid for at least 6 months)
- Taking bone-targeting medication (biphosphonate, teriparatide, strontium ranelate)
Other illness
- History of fracture due to bone fragility
Other
- No sign written consent
- For the controls:
- anti-aromasin or GnRH agonist for at least 6 months,
Who the study is looking for
- For the patients:
- Women or men treated at the Saint-Etienne University Hospital and presenting an osteoporotic risk with one of the following associated pathologies:
- Osteoporosis defined by: History of a documented brittle bone fracture
- Bone fragility: Patient with indication for bone densitometry but no history of fracture
- Inflammatory joint disease:
- Rheumatoid arthritis
- Spondyloarthritis
- Chronic kidney disease
- Endocrinopathies:
- Primary hyperparathyroidism
- Constitutional thinness
- Anorexia nervosa
- Obesity (BMI \>30)
- Sarcopenia
- Neuropathies - Parkinson's disease
- For the controls:
- Acute episode of spinal or radiculalgia (less than one month old) with corticosteroid treatment of less than 1 month Signature of written consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU Saint-Etienne Coordinator of this site? Confirm its status | Saint-Etienne | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.